Company / Operating Income
NewAmsterdam Pharma Co N.V. Operating Income History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$225.7M
FY2025
5-year range
-$225.7M / -$3.6M
FY2021-FY2025
Trend
-28.0%
vs FY2024
Sector context
#147 of 202
Health Care
What the data says
At -$226M, NewAmsterdam Pharma Co N.V.'s operating income ranks #147 of 202 in the Health Care sector. Operating Income has fluctuated over the past 5 years, ranging from -$226M in FY2025 to -$4M in FY2022.
Based on SEC 10-K filings.
-$226M in FY2025.
Declined from -$183M to -$226M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#147 of 202 in Health CareTop 73% of 202This company -$225.7M Sector average $70.7M
▼
-419.2% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 28.0% year-over-year.
- Ranks #147 out of 202 companies in the Health Care sector.
- Peak operating income was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$225.7M | -28.0% |
| FY2024 | -$176.3M | +3.6% |
| FY2023 | -$183.0M | -5043.9% |
| FY2022 | -$3.6M | +89.8% |
| FY2021 | -$35.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026